Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 May 17;18(5):e0285864. doi: 10.1371/journal.pone.0285864

Purification of recombinant bacterial collagens containing structural perturbations

Sonal Gahlawat 1, Vikas Nanda 2,3, David I Shreiber 1,*
Editor: Yong Wang4
PMCID: PMC10191275  PMID: 37196046

Abstract

Streptococcus pyogenes-derived recombinant bacterial collagen-like proteins (CLPs) are emerging as a potential biomaterial for biomedical research and applications. Bacterial CLPs form stable triple helices and lack specific interactions with human cell surface receptors, thus enabling the design of novel biomaterials with specific functional attributes. Bacterial collagens have been instrumental in understanding collagen structure and function in normal and pathological conditions. These proteins can be readily produced in E. coli, purified using affinity chromatography, and subsequently isolated after cleavage of the affinity tag. Trypsin is a widely used protease during this purification step since the triple helix structure is resistant to trypsin digestion. However, the introduction of Gly→X mutations or natural interruptions within CLPs can perturb the triple helix structure, making them susceptible to trypsin digestion. Consequently, removing the affinity tag and isolating collagen-like (CL) domains containing mutations is impossible without degradation of the product. We present an alternative method to isolate CL domains containing Gly→X mutations utilizing a TEV protease cleavage site. Protein expression and purification conditions were optimized for designed protein constructs to achieve high yield and purity. Enzymatic digestion assays demonstrated that CL domains from wild-type CLPs could be isolated by digestion with either trypsin or TEV protease. In contrast, CLPs containing Gly→Arg mutations are readily digested by trypsin while digestion with TEV protease cleaved the His6-tag, enabling the isolation of mutant CL domains. The developed method can be adapted to CLPs containing various new biological sequences to develop multifunctional biomaterials for tissue engineering applications.

Introduction

Over the past two decades, recombinant bacterial collagen from Streptococcus pyogenes has evolved into an indispensable biomaterial to gain insight into the sequence-structure-function relationship of normal and pathological collagens. S. pyogenes produces collagen-like proteins (also known as Scl2 or CLPs) that contain an N-terminal signal sequence, a variable globular domain (V-domain), a collagen-like (CL) triple helix domain consisting of repeating units of (Gly-X-Y)n, and a C-terminal cell wall attachment domain [1]. The V-domain contains a coiled-coil motif and is essential for the trimerization and proper folding of the triple helix [2]. The recombinant CLPs can self-assemble into a stable triple helix structure even in the absence of hydroxyproline residues. The high content of proline residues along with charged and polar residues contribute to the stability of the triple helix via electrostatic interactions [3, 4]. As such, recombinant CLPs exhibit a high thermal stability of 35–39°C, comparable to animal collagen [5, 6]. Unlike animal collagens, CLPs do not inherently bind to human cell surface receptors and other components of the extracellular matrix (ECM) to elicit specific responses [7, 8]. Consequently, they can provide an effective biological control, allowing selective integration of specific human collagen ligand-binding sites to study specific protein-collagen interactions via recombinant DNA technology [913]. Hence, engineered CLPs can be used to probe the structure and function of animal collagen, including single amino acid substitutions and natural interruptions to mimic disease-causing mutations in collagen disorders.

Recombinant CLPs can be easily expressed in E. coli to achieve high protein expression using a cold-shock system that selectively induces expression of the target protein at low temperatures [14]. One of the most common methods to purify these bacterial CLPs is to include a polyhistidine (His6) tag at the N-terminal of the protein, followed by protein purification using immobilized metal affinity chromatography (IMAC) that utilizes the interaction between His6-tagged CLP and immobilized Ni2+ ions supplied by the chromatography matrix. Previous applications of CLPs to study triple helix structure and function all included a trypsin protease site to remove the His6-tag to obtain CL domains from the full-length designed construct [3, 10, 11, 13, 1518]. This was motivated by the established proteolytic resistance of a native collagen triple helix to digestion by trypsin, pepsin, and chymotrypsin (Fig 1) [3, 5, 8, 16, 19]. However, a triple helix with disruptions and a partially folded structure is sensitive to digestion [20, 21]. Therefore, recombinant CLPs containing natural interruptions and mutations that could potentially disrupt the triple helical structure become susceptible to trypsin digestion (Fig 1) [2227]. As a result, it is very challenging to remove the His6-tag or any other affinity tag without disrupting the triple helix structure of the proteins, and researchers who have used CLPs to study these kinds of interruptions forgo the cleavage step and leave the His6-tag intact.

Fig 1. Schematic illustration of disrupted triple helix digestion by trypsin and TEV protease.

Fig 1

(A) An intact triple helix is resistant to digestion by trypsin. (B) Due to mutations and natural interruptions, the triple helix become susceptible to trypsin digestion, which might result in protein degradation. In contrast, TEV protease does not degrade disrupted triple helix, enabling the isolation of mutant triple helices for more precise characterization and functional studies and for use as a potential biomaterial.

We developed an efficient and reproducible purification protocol to isolate recombinant CLPs with structural perturbations by incorporating a Tobacco Etch Virus (TEV) protease cleavage site. Structurally distorted triple helices were generated through the introduction of Gly→Arg mutations within the integrin-binding site of CL domains. The Gly→Arg mutation would provide differential folding effects and has been associated with collagen disorders, including Osteogenesis Imperfecta and Ehlers-Danlos Syndrome and its subtypes (https://eds.gene.le.ac.uk/). The TEV protease is responsible for cleaving the His-tag from the designed full-length construct, while trypsin can be used to investigate the structural integrity of the triple helix (Fig 1). Optimization of protein expression and purification was performed to maximize bacterial CLPs production. Several parameters were examined that could affect protein expression, including bacterial host strain, culture media, and inducer concentration. The results indicate that this method can be applied to express and purify recombinant CLPs with sequences of varied molecular flexibility to obtain CL domains for downstream applications, including biophysical characterization of mutant proteins and study of cell function and behavior due to the included mutation(s).

Materials and methods

Chemicals and reagents

Sodium phosphate monobasic (AC389870025), sodium phosphate dibasic (S374-500), imidazole (AC122025000), carbenicillin (BP26485), tryptone (BP1421-2), yeast extract (BP9727-2), and Luria Broth (LB) Agar (BP9724-500) were purchased from Fisher Scientific. Dialysis tubing cellulose membrane (D9527-100FT), acetic acid (695092–2.5L), trypsin (T1426-50MG), and Amicon® Ultra-15 Centrifugal Filter Unit (UFC901024) were purchased from Millipore Sigma. Sodium Chloride (0241–2.5KG) was purchased from VWR. Ni -NTA Agarose (30210) was purchased from Qiagen. 4X Laemmli sample buffer (1610737), Precision Plus protein dual color standard (1610374), 4–15% Mini-PROTEAN® TGX™ Precast Protein Gels (4561086), and 2-mercaptoethanol (1610710) were purchased from Bio-Rad Laboratories. BL21-DE3 competent cells (C2527I) were purchased from New England BioLabs. Isopropylthio-β-galactoside, IPTG, (I2481C50) was purchased from Gold Biotechnology. Collagen-I (C857) was purchased from Elastin Products Company, Inc. pCold-I expression vector was purchased Takara Bio Inc.

Design of recombinant bacterial CLPs

The gene constructs used for bacterial CLPs are based on the DNA sequence for the fragment of the Scl2.28 allele of S. pyogenes encoding for the combined globular and collagen-like proteins but lacking the C-terminal domain, as previously described [1, 3, 5, 8, 24]. In brief, constructs included an N-terminal globular domain (V) followed by two CL domains. An enzymatic cleavage site was introduced between the V-domain and the two following CL domains to facilitate isolation of the CL domains. Constructs contained either the trypsin cleavage sequence (LVPR↓GSP) or the TEV protease sequence (ENLYFQ↓G). This DNA sequence, termed VCL2, was synthesized commercially with codon optimization for expression in E. coli (GenScript, Piscataway, New Jersey), and served as the template for creating the mutant construct with a Gly-to-Arg mutation at residue #201 and #444 within the IBS of each CL domain, which was denoted VCL2(G→R). The sequences of the final constructs were confirmed by sequencing prior to transformation and protein expression. The final DNA sequences of all recombinant bacterial collagens were cloned into the pCold-I vector systems (GenScript, Piscataway, New Jersey) for expression in E. coli. The constructs also included an N-terminal His6-tag that was provided by the pCold-I vector for protein purification.

Expression and purification of the proteins

All constructs were transformed into E. coli BL21-DE3 strain. For protein expression, a positive clone was selected for the primary culture and was grown in LB media with 100 μg/mL ampicillin at 37°C with shaking at 250 RPM for overnight. The following day, the primary culture was used to inoculate 1L of 2X YT medium (10 gm/L yeast extract, 16 gm/L tryptone, and 5 gm/L NaCl, pH 7.4) with ampicillin (100 μg/mL). The cells were grown at 37°C with shaking until the A600 absorbance reading reached an optical density in the range of 0.4 to 0.6 A.U. Subsequently, the cells were cooled down to 25°C for 1 hour, and 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was added for protein induction. After 10 hours of protein induction, the cells were further cooled to 15°C for 14 hours, after which the cells were harvested by centrifugation (4,000 RPM, 20 mins, 4°C). The cell pellet was stored at -80°C until further use.

For protein extraction, the cell pellet was thawed and resuspended in lysis buffer, and the cells were ruptured by sonication in ice water for 10 mins (30 sec ON and 30 sec OFF cycle at 40% amplitude). Clarified lysate was obtained by centrifugation at 18,000 RPM for 30 mins at 4°C. The His-tagged recombinant proteins were purified by immobilized metal affinity chromatography (IMAC) using Ni2+ charged affinity resin (Ni-NTA, Qiagen, Germantown, Maryland). To aid in the binding of Ni2+ with His-tagged protein, the clarified lysate was incubated with Ni-NTA, pre-equilibrated with binding buffer with gentle shaking at 4°C. (NOTE: for a cell pellet obtained from 500 mL bacterial culture, 2 gravity columns were used for the purification with each column containing approximately 5 mL of Ni-NTA resin.) After an hour of incubation, the column was washed with (i) 20 column volumes (CV) of binding buffer (50 mM sodium phosphate buffer, 500 mM of sodium chloride, and 10 mM of imidazole, pH 8), (ii) 20 CV of high-salt buffer (50 mM sodium phosphate buffer, 1 M of sodium chloride, and 10 mM of imidazole, pH 8), and (iii) 15–20 CV of low imidazole buffer (50 mM sodium phosphate buffer, 500 mM of sodium chloride, and 50 mM of imidazole, pH 8) to remove the non-specific proteins bound to the resin. Finally, the protein was eluted in a step gradient of imidazole concentration (100 mM, 250 mM, and 500 mM and pH 8) with three fractions (10 mL each) collected for each concentration. The purification buffers contained β-mercaptoethanol (BME) as the reducing agent to prevent any disulfide bonds formation. All fractions containing the protein were collected and verified for purity level with SDS-PAGE. Eluted fractions containing the protein were pooled and dialyzed against 5 mM sodium phosphate buffer, pH 7.4 for 48 hours with three buffer changes. The dialyzed protein was lyophilized and stored at -80°C.

Enzymatic digestion assay

Enzymatic digestion assays were performed to examine the structural stability of triple helix. All recombinant proteins were digested with either trypsin or TEV protease at a ratio of 1:25 and 1:10, respectively, at 20°C for 2 mins, 5 mins, 15 mins, or overnight (16 hours). After digestion, the reaction was stopped by adding 4X SDS sample buffer (3:1 ratio) and heating the samples to 95°C for 5 mins. The digestion profile of the constructs was analyzed by SDS-PAGE.

Results

Design and expression of recombinant constructs with trypsin and TEV protease sites

The control protein, referred to as VCL2, includes an N-terminal V-domain and two tandem CL domains (CL2), which are separated by the linker sequence GAAGVM (Fig 2A). Each of the two CL domains included an integrin binding site (IBS), GFPGER, integrated within the triple helix structure for cell binding. GGPCPPC sequences were inserted at the N- and C-terminal of the CL domains to aid in stability and allow subsequent functionalization for downstream applications. The VCL2(G→R) mutant protein includes a single Gly→Arg mutation (GFPRER) near the middle of the CL domain within the IBS sequence to have minimum impact on the folding and assembly of the triple helix (Fig 2B).

Fig 2. Schematic illustration of the design of recombinant bacterial collagens.

Fig 2

(A) VCL2 with a protease cleavage site (highlighted by “↑”) and an IBS within each CL domain. (B) Version of the VCL2 construct with Gly→Arg within the IBS, where the second Gly residue of GFPGER was mutated to Arg (highlighted by “★”). The ‘CPPC’ domains represent the amino acid sequences inserted at the N- and C- terminal of the CL domains to aid in stability. (C) Description of the designed protein constructs.

Lastly, the introduction of two different enzymatic cleavage sites between the V-domain and CL2 domains allowed us to remove His6-tag and isolate CL domains from the full-length constructs. Four different types of constructs were designed for protein expression and purification: VCL2-Trypsin, VCL2-TEV, VCL2(G→R)-Trypsin, and VCL2(G→R)-TEV (Fig 2C).

We used the cold-shock pCold-I vector system to express and purify recombinant CLPs with and without specific Gly→X mutations. Recombinant protein overexpression at low temperatures often improves protein solubility and stability [14]. We optimized the protein expression by comparing different E. coli strains (BL21 vs. BL21-DE3), culture media (TB vs. 2X YT), and inducer concentration (0–1 mM). We initially utilized the BL21 bacterial strain for the expression of the VCL2 protein, since protein expression was driven by the cold-shock promoter, unlike a traditional T7 RNA polymerase-based vector, where protein expression is strictly controlled by the inducer. Purification of BL21-expressed protein resulted in target protein and a dominant lower molecular weight band that is likely a CL2 degradation product (Fig 3A). By switching to BL21-DE3 bacterial strain, we nearly eliminated the second band (Fig 3A).

Fig 3. Protein expression of VCL2 was optimized to achieve high expression and protein solubility.

Fig 3

(A) SDS-PAGE of the VCL2 purified proteins expressed in E. coli BL21 and BL21-DE3. Protein expression in BL21-DE3 cells resulted in purification of VCL2 with high purity, without any degradation products. (B) SDS-PAGE of insoluble fractions (IF) and soluble fractions (SF) of VCL2 after induction with varying IPTG concentrations, where lower IPTG concentrations induced high protein expression. Molecular Weight standards are in kDa. Conc. = Concentration.

To improve expression and solubility, we tested different IPTG concentrations. High protein expression was obtained using lower IPTG concentrations (0.05 and 0.01 mM, Fig 3B) and inducing protein expression at the mid-exponential growth phase using 2X YT media vs. TB media. Protein expression using TB media led to high protein loss in inclusion bodies, which could not be recovered using detergents. To identify the optimal conditions for protein expression, we selected conditions that led to high protein expression in the soluble fraction and a low expression in the insoluble fraction. Testing various IPTG concentrations allowed us to identify an optimal level of inducer for protein expression with minimal protein loss in inclusion bodies. The combination of low temperatures and lower IPTG concentrations enhanced both protein expression and solubility.

A bench-scale purification of all constructs was carried out at 4°C. The His6-tag at the N-terminal allowed protein purification by IMAC using a Ni-NTA resin, resulting in pure samples for each protein construct as verified by SDS-PAGE (Fig 4). We also utilized an imidazole gradient to obtain a high yield with maximum purity. We used three concentrations of imidazole (100 mM, 250 mM, and 500 mM) to elute the protein and determine the optimal concentration for elution of the protein. Three different fractions were collected for each imidazole concentration to separate contaminants not removed during washing and to achieve full recovery of the target protein.

Fig 4. Ni-NTA purification of expressed proteins lead to high purity.

Fig 4

SDS-PAGE of the purified proteins, (A) VCL2-Trypsin, (B) VCL2-TEV, (C) VCL2(G→R)-Trypsin, and (D) VCL2(G→R)-TEV. Cell lysate was incubated with Ni-NTA resin and FT was collected. The column was washed with binding buffer, high salt buffer, and low imidazole buffer to remove non-specific bound proteins. His-tagged protein was eluted with buffer containing 100 mM (Elution-I), 250 mM (Elution-II), and 500 mM (Elution-III) imidazole with three fractions collected per concentration. Molecular weight standards in kDa, Ly = lysate, and FT = Flowthrough (containing the unbound protein).

The monomeric molecular weight of VCL2-Trypsin, VCL2-TEV, VCL2(G→R)-Trypsin, and VCL2(G→R)-TEV are 57.24 kDa, 57.41 kDa, 57.55 kDa, and 57.61 kDa, respectively. On SDS-PAGE, the protein bands for monomeric chains were higher than expected, which has previously been shown for proteins with rod-like structures [3]. The protein purity was sufficient to examine the effectiveness of each protease to isolate CL domains with and without Gly→X mutations.

High protein expression in all constructs was seen, as demonstrated by the high-intensity band in loaded lysates on the SDS-PAGE. Such high protein expression led to inefficient binding of the protein with Ni-NTA resin, resulting in protein elution during sample loading, despite a variety of attempts to improve the binding efficiency, including optimization of the binding buffer with varying concentrations of imidazole and detergents, purification under denaturing conditions, changing the incubation time between the protein and resin, and increasing the volume of the resin. Recovery of the protein lost in the flow-through was easily achieved by performing multiple rounds of purification using the collected flow-through. Alternatively, larger-sized gravity columns or high-performance liquid chromatography (HPLC) instruments can be utilized to attain high yields in one-step purification.

Structural perturbation in triple helix increases susceptibility to trypsin digestion

Trypsin digestion assays are one of the most common techniques employed to examine the structural stability of triple helices. Mutations that disrupt the triple helix conformation can increase proteolytic susceptibility. As expected, trypsin digestion of VCL2-Trypsin cleaves the His6-tag and V-domain, allowing the isolation of CL2 protein (Fig 5A). The presence of an extra band is observed, which suggests digestion of a small fraction of unfolded CL2. However, the introduction of Gly→Arg within the IBS of bacterial collagen, VCL2(G→R)-Trypsin, increased sensitivity to trypsin digestion with detectable CL2 cleavage products after only 2 minutes (Fig 5B). This is consistent with the highly disruptive nature of Gly→Arg substitutions within the triple helix [22, 2830]. After overnight digestion with trypsin, the VCL2(G→R)-Trypsin protein is entirely degraded, hampering purification and significantly reducing the final yield of CL2(G→R).

Fig 5. Incubation of distorted triple helices with trypsin demonstrated protein digestion while incubation with TEV protease allowed isolation of CL domains containing Gly→X mutations.

Fig 5

SDS-PAGE of (A) VCL2-Trypsin, (B) VCL2(G→R)-Trypsin, (C)VCL2-TEV, (D) VCL2(G→R)-TEV, and (E) VCL2(G→R)-TEV purified proteins digested with either trypsin or TEV protease for different time points (0 mins, 2 mins, 15 mins, and O/N). Digestion of VCL2 with trypsin and TEV protease resulted in removal of His6-tag and V-domain and isolation of CL2. However, digestion of VCL2(G→R) with trypsin led to protein digestion starting at 2 mins only. Digestion of VCL2(G→R)-TEV with TEV protease resulted in the isolation of CL2(G→R) protein without degrading the protein. Molecular weight standards in kDa, O/N = Overnight digestion with the protease.

TEV protease sites facilitate purification of CL domains containing structural perturbations

To minimize proteolysis of CL2(G→R) during purification, we synthesized VCL2 and VCL2(G→R) constructs containing the TEV protease cleavage site. The digestion profile of VCL2-TEV with TEV protease was similar to that of VCL2-Trypsin digested with trypsin (Fig 5C). While trypsin digestion of VCL2(G→R)-Trypsin produced multiple degradation products, TEV protease digestion of VCL2(G→R)-TEV only produced the His6-tag + V-domain and the target CL2(G→R) (Fig 5D). As expected, trypsin digestion of VCL2(G→R)-TEV produced multiple degradation products (Fig 5E). These results confirm that the purification of intact CL domains with G→X mutations can be achieved by replacing trypsin with TEV protease. Replacing the trypsin cleavage site with TEV offers a reliable method to isolate CL domains containing structural perturbations irrespective of the type of substituted amino acid, the location of the mutation, and the surrounding local sequence, all of which play a decisive role in determining the conformation and stability of the triple helix.

Discussion

Given that CLPs are increasingly used in collagen-based biomaterials and as tools for understanding collagen structure and function [3136], it is critical to develop effective methods for purifying and studying them. The inclusion of the His6-tag at the N-terminal sequence allowed the purification of expressed CLPs using IMAC, which can be easily scaled up. However, isolating CL domains and removing the His6-tag (or any other affinity tag) using current protocols depends on the formation of a fully-folded, triple helix structure.

We have developed a robust protocol for isolating full-length recombinant CLPs containing structural perturbations due to Gly→X mutations. Bacterial CLPs are often engineered to incorporate specific sequences of interest, such as Gly→X mutations and other natural interruptions, to study collagen’s structure and function, especially in inherited collagen disorders. Such modifications could also be used to alter biomaterial mechanics or tailor cell-biomaterial interactions. While existing protocols based on trypsin digestion provide a reliable tool to investigate the impact of Gly substitutions on triple helix structure, the use of the same enzyme for purification restricts our ability to obtain full-length recombinant collagens containing Gly substitutions.

In this study, we identified shake flask culture conditions that maximize bacterial CLP expression. Selecting a suitable E. coli strain proved an essential step since the type of strain had a major impact on protein expression, solubility, and yield. Moreover, culture media composition and conditions affect bacterial growth, which will ultimately impact protein expression and solubility. By sampling culture media and inducer concentration, we were able to obtain high protein yields. Furthermore, to prevent unwanted degradation products, we incorporated a TEV protease cleavage site instead of the widely-used trypsin site to remove the His6-tag and V-domain. This enabled the isolation of the CL domains containing Gly→Arg mutation within the IBS of CL domain. This method can be further adapted to engineering CLPs containing multiple G→X mutations, ligand-binding sites, natural interruptions, or other sequences of interest that are found in animal collagens that are anticipated to compromise triple helix integrity.

Conclusions

While trypsin is a widely used protease to extract and purify animal collagens for commercial applications, low-substrate specificity and the promiscuous nature of the protease suggest a high potential for mis-cleavages at undesired locations, resulting in irreproducible and unpredictable results. This is particularly important when designing a tailored biomaterial using recombinant bacterial collagens for biomedical applications. Human collagen consists of regions with variable flexibility, which play a crucial role in imparting structural and functional properties in their native environment. Engineering CLPs with specific biological functionality, including cell-cell and cell-ECM interactions or cell-guided degradation, requires incorporating human collagen sequences that can alter the triple helix structure of these fabricated biomaterials. Thus, our method offers one approach to introduce a wide range of sequences to develop advanced biomaterials for tissue engineering applications. This technology provides a versatile platform to design novel biomaterials, where the introduction of multiple biological motifs could potentially impact the triple helix structure.

Supporting information

S1 File

(PDF)

Acknowledgments

The authors acknowledge Natalie Losada and Dr. Eddy Arnold (Center for Advanced Biotechnology and Medicine, Rutgers University) for providing access to protein purification resources and Jennifer Timm (Department of Marine and Coastal Sciences and Center for Advanced Biotechnology and Medicine, Rutgers University) for providing valuable expertise in protein purification methodology and sharing the TEV protease.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This research was supported by the New Jersey Health Foundation (Grant/Award Number: PC101-20, https://www.njhealthfoundation.org) and The Marfan Foundation (Grant/Award Number: 127611, https://marfan.org) awarded to D.I.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Xu Y, Keene DR, Bujnicki JM, Höök M, Lukomski S. Streptococcal Scl1 and Scl2 Proteins Form Collagen-like Triple Helices. J Biol Chem. 2002. Jul 26;277(30):27312–8. doi: 10.1074/jbc.M201163200 [DOI] [PubMed] [Google Scholar]
  • 2.Squeglia F, Bachert B, De Simone A, Lukomski S, Berisio R. The Crystal Structure of the Streptococcal Collagen-like Protein 2 Globular Domain from Invasive M3-type Group A Streptococcus Shows Significant Similarity to Immunomodulatory HIV Protein gp41. J Biol Chem. 2014. Feb 21;289(8):5122–33. doi: 10.1074/jbc.M113.523597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Yoshizumi A, Yu Z, Silva T, Thiagarajan G, Ramshaw JAM, Inouye M, et al. Self-association of streptococcus pyogenes collagen-like constructs into higher order structures. Protein Sci. 2009. Jun;18(6):1241–51. doi: 10.1002/pro.134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Privalov PL, Tiktopulo EI, Tischenko VM. Stability and mobility of the collagen structure. J Mol Biol. 1979. Jan 15;127(2):203–16. doi: 10.1016/0022-2836(79)90240-7 [DOI] [PubMed] [Google Scholar]
  • 5.Yu Z, An B, Ramshaw JAM, Brodsky B. Bacterial collagen-like proteins that form triple-helical structures. J Struct Biol. 2014. Jun;186(3):451–61. doi: 10.1016/j.jsb.2014.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Han R, Zwiefka A, Caswell CC, Xu Y, Keene DR, Lukomska E, et al. Assessment of prokaryotic collagen-like sequences derived from streptococcal Scl1 and Scl2 proteins as a source of recombinant GXY polymers. Appl Microbiol Biotechnol. 2006. Aug;72(1):109–15. doi: 10.1007/s00253-006-0387-5 [DOI] [PubMed] [Google Scholar]
  • 7.Cosgriff-Hernandez E, Hahn MS, Russell B, Wilems T, Munoz-Pinto D, Browning MB, et al. Bioactive hydrogels based on Designer Collagens. Acta Biomater. 2010. Oct;6(10):3969–77. doi: 10.1016/j.actbio.2010.05.002 [DOI] [PubMed] [Google Scholar]
  • 8.An B, Kaplan DL, Brodsky B. Engineered recombinant bacterial collagen as an alternative collagen-based biomaterial for tissue engineering. Front Chem. 2014;2:40. doi: 10.3389/fchem.2014.00040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Diaz Quiroz JF, Rodriguez PD, Erndt-Marino JD, Guiza V, Balouch B, Graf T, et al. Collagen-mimetic proteins with tunable integrin binding sites for vascular graft coatings. ACS Biomater Sci Eng. 2018. Aug 13;4(8):2934–42. doi: 10.1021/acsbiomaterials.8b00070 [DOI] [PubMed] [Google Scholar]
  • 10.Parmar PA, Chow LW, St-Pierre JP, Horejs CM, Peng YY, Werkmeister JA, et al. Collagen-mimetic peptide-modifiable hydrogels for articular cartilage regeneration. Biomaterials. 2015. Jun;54:213–25. doi: 10.1016/j.biomaterials.2015.02.079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Parmar PA, St-Pierre JP, Chow LW, Spicer CD, Stoichevska V, Peng YY, et al. Enhanced articular cartilage by human mesenchymal stem cells in enzymatically mediated transiently RGDS-functionalized collagen-mimetic hydrogels. Acta Biomater. 2017. Mar 15;51:75–88. doi: 10.1016/j.actbio.2017.01.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Xu K, Nowak I, Kirchner M, Xu Y. Recombinant Collagen Studies Link the Severe Conformational Changes Induced by Osteogenesis Imperfecta Mutations to the Disruption of a Set of Interchain Salt Bridges. J Biol Chem. 2008. Dec 5;283(49):34337–44. doi: 10.1074/jbc.M805485200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Peng YY, Stoichevska V, Schacht K, Werkmeister JA, Ramshaw JAM. Engineering multiple biological functional motifs into a blank collagen-like protein template from Streptococcus pyogenes. J Biomed Mater Res A. 2014. Jul;102(7):2189–96. doi: 10.1002/jbm.a.34898 [DOI] [PubMed] [Google Scholar]
  • 14.Qing G, Ma LC, Khorchid A, Swapna GVT, Mal TK, Takayama MM, et al. Cold-shock induced high-yield protein production in Escherichia coli. Nat Biotechnol. 2004. Jul;22(7):877–82. doi: 10.1038/nbt984 [DOI] [PubMed] [Google Scholar]
  • 15.Peng YY, Yoshizumi A, Danon SJ, Glattauer V, Prokopenko O, Mirochnitchenko O, et al. A Streptococcus pyogenes derived collagen-like protein as a non-cytotoxic and non-immunogenic cross-linkable biomaterial. Biomaterials. 2010. Apr;31(10):2755–61. doi: 10.1016/j.biomaterials.2009.12.040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Peng YY, Stoichevska V, Madsen S, Howell L, Dumsday GJ, Werkmeister JA, et al. A simple cost effective methodology for large scale purification of recombinant non-animal collagens. Appl Microbiol Biotechnol. 2014. Feb;98(4):1807–15. doi: 10.1007/s00253-013-5475-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Stoichevska V, Peng YY, Vashi AV, Werkmeister JA, Dumsday GJ, Ramshaw JAM. Engineering specific chemical modification sites into a collagen-like protein from Streptococcus pyogenes. J Biomed Mater Res A. 2017. Mar;105(3):806–13. doi: 10.1002/jbm.a.35957 [DOI] [PubMed] [Google Scholar]
  • 18.Parmar PA, Skaalure SC, Chow LW, St-Pierre JP, Stoichevska V, Peng YY, et al. Temporally degradable collagen-mimetic hydrogels tuned to chondrogenesis of human mesenchymal stem cells. Biomaterials. 2016. Aug;99:56–71. doi: 10.1016/j.biomaterials.2016.05.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Peng YY, Howell L, Stoichevska V, Werkmeister JA, Dumsday GJ, Ramshaw JAM. Towards scalable production of a collagen-like protein from Streptococcus pyogenes for biomedical applications. Microbial Cell Factories. 2012. Nov 5;11(1):146. doi: 10.1186/1475-2859-11-146 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bruckner P, Prockop DJ. Proteolytic enzymes as probes for the triple-helical conformation of procollagen. Anal Biochem. 1981. Jan 15;110(2):360–8. doi: 10.1016/0003-2697(81)90204-9 [DOI] [PubMed] [Google Scholar]
  • 21.Ryhänen L, Zaragoza EJ, Uitto J. Conformational stability of type I collagen triple helix: evidence for temporary and local relaxation of the protein conformation using a proteolytic probe. Arch Biochem Biophys. 1983. Jun;223(2):562–71. doi: 10.1016/0003-9861(83)90621-5 [DOI] [PubMed] [Google Scholar]
  • 22.Cheng H, Rashid S, Yu Z, Yoshizumi A, Hwang E, Brodsky B. Location of Glycine Mutations within a Bacterial Collagen Protein Affects Degree of Disruption of Triple-helix Folding and Conformation. J Biol Chem. 2011. Jan 21;286(3):2041–6. doi: 10.1074/jbc.M110.153965 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hwang ES, Brodsky B. Folding delay and structural perturbations caused by type IV collagen natural interruptions and nearby Gly missense mutations. J Biol Chem. 2012. Feb 3;287(6):4368–75. doi: 10.1074/jbc.M111.269084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Yigit S, Yu H, An B, Hamaia S, Farndale RW, Kaplan DL, et al. Mapping the Effect of Gly Mutations in Collagen on α2β1 Integrin Binding. J Biol Chem. 2016. 02;291(36):19196–207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Chhum P, Yu H, An B, Doyon BR, Lin YS, Brodsky B. Consequences of Glycine Mutations in the Fibronectin-binding Sequence of Collagen. J Biol Chem. 2016. Dec 30;291(53):27073–86. doi: 10.1074/jbc.M116.753566 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Qiu Y, Mekkat A, Yu H, Yigit S, Hamaia S, Farndale RW, et al. Collagen Gly missense mutations: Effect of residue identity on collagen structure and integrin binding. J Struct Biol. 2018;203(3):255–62. doi: 10.1016/j.jsb.2018.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yeo J, Qiu Y, Jung GS, Zhang YW, Buehler MJ, Kaplan DL. Adverse effects of Alport syndrome-related Gly missense mutations on collagen type IV: Insights from molecular simulations and experiments. Biomaterials. 2020. May;240:119857. doi: 10.1016/j.biomaterials.2020.119857 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hoop CL, Kemraj AP, Wang B, Gahlawat S, Godesky M, Zhu J, et al. Molecular underpinnings of integrin binding to collagen mimetic peptides containing vascular Ehlers-Danlos syndrome-associated substitutions. J Biol Chem. 2019. Aug 12;jbc.RA119.009685. doi: 10.1074/jbc.RA119.009685 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Xiao J, Madhan B, Li Y, Brodsky B, Baum J. Osteogenesis Imperfecta Model Peptides: Incorporation of Residues Replacing Gly within a Triple Helix Achieved by Renucleation and Local Flexibility. Biophysical Journal. 2011. Jul 20;101(2):449–58. doi: 10.1016/j.bpj.2011.06.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Persikov AV, Ramshaw JAM, Brodsky B. Prediction of Collagen Stability from Amino Acid Sequence*. Journal of Biological Chemistry. 2005. May 13;280(19):19343–9. doi: 10.1074/jbc.M501657200 [DOI] [PubMed] [Google Scholar]
  • 31.Picker J, Lan Z, Arora S, Green M, Hahn M, Cosgriff-Hernandez E, et al. Prokaryotic Collagen-Like Proteins as Novel Biomaterials. Front Bioeng Biotechnol. 2022. Mar 17;10:840939. doi: 10.3389/fbioe.2022.840939 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Meganathan I, Pachaiyappan M, Aarthy M, Radhakrishnan J, Mukherjee S, Shanmugam G, et al. Recombinant and genetic code expanded collagen-like protein as a tailorable biomaterial. Mater Horiz. 2022. Oct 31;9(11):2698–721. doi: 10.1039/d2mh00652a [DOI] [PubMed] [Google Scholar]
  • 33.Browning MB, Dempsey D, Guiza V, Becerra S, Rivera J, Russell B, et al. Multilayer vascular grafts based on collagen-mimetic proteins. Acta Biomater. 2012. Mar;8(3):1010–21. doi: 10.1016/j.actbio.2011.11.015 [DOI] [PubMed] [Google Scholar]
  • 34.Merrett K, Wan F, Lee CJ, Harden JL. Enhanced Collagen-like Protein for Facile Biomaterial Fabrication. ACS Biomater Sci Eng. 2021. Apr 12;7(4):1414–27. doi: 10.1021/acsbiomaterials.1c00069 [DOI] [PubMed] [Google Scholar]
  • 35.Cereceres S, Touchet T, Browning MB, Smith C, Rivera J, Höök M, et al. Chronic Wound Dressings Based on Collagen-Mimetic Proteins. Adv Wound Care (New Rochelle). 2015. Aug 1;4(8):444–56. doi: 10.1089/wound.2014.0614 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Parmar PA, St-Pierre JP, Chow LW, Puetzer JL, Stoichevska V, Peng YY, et al. Harnessing the Versatility of Bacterial Collagen to Improve the Chondrogenic Potential of Porous Collagen Scaffolds. Adv Healthc Mater. 2016. Jul;5(13):1656–66. doi: 10.1002/adhm.201600136 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Yong Wang

23 Mar 2023

PONE-D-23-06762Purification of recombinant bacterial collagens containing structural perturbationsPLOS ONE

Dear Dr. Shreiber,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 07 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Yong Wang

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

Additional Editor Comments (if provided):

Comments from Reviewer#1:

This manuscript by Gahlawat et al described a simple laboratory effort to purify a collagen like protein (CLP) having Gly-to-X mutations that was first expressed as a fusion protein. They provided evidence showing protease TEV is better suited for the removal of the His-tagged V-domain than trypsin because of the folding problem related to the mutation. Yet, there is no data and no mention on the folding of the peptides. Did the digestion act on monomer during purification or on folded trimer? Can the triple helix form without the removal of V-domain? If not, how can they claim the varied sensitivity of the fusion protein to proteases is related to the ‘partially folded structure’?

Other major problems:

Figure 1 is missing.

The optimization experiments are notoriously difficult to reproduce. The authors did not mention the reproducibility of the results.

Overall, the work felt like an incomplete effort and did not have enough reproducible results to meet the requirement of a research article.

Comments from Reviewer#2:

The authors present an alternative method for purifying recombinant bacterial collagens (Collagen-like proteins, CLP) containing structural perturbations or more specifically the mutation Gly to Arg. The motivation for developing the purification method is that the widely used purification method, which uses trypsin digestion to remove the affinity tag, also degrade the structural altered CLP. Instead of trypsin, TEV protease and TEV protease cleavage is used for removal of the affinity tag.

In total the authors make four constructs with TEV or Trypsin cleavage sites combined with native CLP or CLP containing the Gly-Arg mutations. By blabla and enzymatic digestion assay, they demonstrate that CLPs containing Gly→Arg mutations are readily digested by trypsin while digestion with TEV protease only cleaved the affinity tag.

The manuscript would benefit from:

• Specify the rationale for choosing to substitute Glycine with Arginine

• Indicate the number of the amino acid substitution or specify which glycine was substituted in the integrin binding site.

• Reference for the contribution of the mutation Gly to Arg change the structure of CLP

• Reference or argument that Gly to X would have same effect as Gly to Arg

• Figure 1:

o Panel C: Missing figure text.

o Panel A:

� Exchange “Protease cleavage sites” with “TEV or Trypsin cleavage site”.

� Specify which glycine was mutated in the integrin binding site

• Line 79: forgo --> forgot

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors present an alternative method for purifying recombinant bacterial collagens (Collagen-like proteins, CLP) containing structural perturbations or more specifically the mutation Gly to Arg. The motivation for developing the purification method is that the widely used purification method, which uses trypsin digestion to remove the affinity tag, also degrade the structural altered CLP. Instead of trypsin, TEV protease and TEV protease cleavage is used for removal of the affinity tag.

In total the authors make four constructs with TEV or Trypsin cleavage sites combined with native CLP or CLP containing the Gly-Arg mutations. By blabla and enzymatic digestion assay, they demonstrate that CLPs containing Gly→Arg mutations are readily digested by trypsin while digestion with TEV protease only cleaved the affinity tag.

The manuscript would benefit from:

• Specify the rationale for choosing to substitute Glycine with Arginine

• Indicate the number of the amino acid substitution or specify which glycine was substituted in the integrin binding site.

• Reference for the contribution of the mutation Gly to Arg change the structure of CLP

• Reference or argument that Gly to X would have same effect as Gly to Arg

• Figure 1:

o Panel C: Missing figure text.

o Panel A:

� Exchange “Protease cleavage sites” with “TEV or Trypsin cleavage site”.

� Specify which glycine was mutated in the integrin binding site

• Line 79: forgo forgot

Reviewer #2: This manuscript by Gahlawat et al described a simple laboratory effort to purify a collagen like protein (CLP) having Gly-to-X mutations that was first expressed as a fusion protein. They provided evidence showing protease TEV is better suited for the removal of the His-tagged V-domain than trypsin because of the folding problem related to the mutation. Yet, there is no data and no mention on the folding of the peptides. Did the digestion act on monomer during purification or on folded trimer? Can the triple helix form without the removal of V-domain? If not, how can they claim the varied sensitivity of the fusion protein to proteases is related to the ‘partially folded structure’?

Other major problems:

Figure 1 is missing.

The optimization experiments are notoriously difficult to reproduce. The authors did not mention the reproducibility of the results.

Overall, the work felt like an incomplete effort and did not have enough reproducible results to meet the requirement of a research article.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

<quillbot-extension-portal></quillbot-extension-portal>

PLoS One. 2023 May 17;18(5):e0285864. doi: 10.1371/journal.pone.0285864.r002

Author response to Decision Letter 0


26 Apr 2023

PONE-D-23-06762

Purification of recombinant bacterial collagens containing structural perturbations

We would like to thank the reviewers for their effort and time in reviewing the manuscript. We sincerely appreciate their valuable and insightful comments, which helped us in improving the quality of the manuscript. We have addressed the comments specific to each reviewer below. We have uploaded this in a formatted version with the added figure to the revised documents, labeled "Response to Reviewers".

Reviewer 1

1. Specify the rationale for choosing to substitute Glycine with Arginine.

Thank you for the suggestion. We have included the rationale for choosing Gly→Arg mutation in lines 83-87.

Lines 83-87:

Structurally distorted triple helices were generated through the introduction of Gly→Arg mutations within the integrin-binding site of CL domains. The Gly→Arg mutation would provide differential folding effects and has been associated with collagen disorders, including Osteogenesis Imperfecta and Ehlers-Danlos Syndrome and its subtypes (https://eds.gene.le.ac.uk/).

2. Indicate the number of the amino acid substitution or specify which glycine was substituted in the integrin binding site.

As listed in lines 120-122, Gly at position #201 and #444 were mutated to Arg residues. Within the integrin-binding site, GFPGER, the second Gly residue (highlighted in bold) was mutated to Arg amino acid, which has further explained in lines 176-178 and Fig 2 legend.

Lines 176-178:

The VCL2(G→R) mutant protein includes a single Gly→Arg mutation (GFPRER) near the middle of the CL domain within the IBS sequence to have minimum impact on the folding and assembly of the triple helix

Fig 2B:

Version of the VCL2 construct with Gly→Arg within the IBS, where the second Gly residue of GFPGER was mutated to Arg (highlighted by “★”).

3. Reference for the contribution of the mutation Gly to Arg change the structure of CLP.

Reference 22 (line 238) supports the impact of Gly→Arg mutation on the triple helix structure. Additional references have been added in support of the argument (28-30).

4. Reference or argument that Gly to X would have same effect as Gly to Arg.

We have added text in lines 252-256 justifying this claim.

Lines 252-256:

Replacing the trypsin cleavage site with TEV offers a reliable method to isolate CL domains containing structural perturbations irrespective of the type of substituted amino acid, the location of the mutation, and the surrounding local sequence, all of which play a decisive role in determining the conformation and stability of the triple helix.

5. Figure 1:

a. Panel C: Missing figure text.

It is unclear which figure text is missing. The submitted Fig 2C contains a table, which describes the design of protein constructs, including the presence or absence of Gly substitution and the type of protease cleavage site (trypsin vs. TEV).

b. Panel A:

i. Exchange “Protease cleavage sites” with “TEV or Trypsin cleavage site”.

ii. Specify which glycine was mutated in the integrin binding site

i. We have exchanged the “protease cleavage sites” with “TEV or Trypsin cleavage site” in Fig 2A.

ii. We have updated the Fig 2B legend to highlight which Gly residue was mutated to Arg within the integrin-binding site.

Fig 2B:

Version of the VCL2 construct with Gly→Arg within the IBS, where the second Gly residue of GFPGER was mutated to Arg (highlighted by “★”).

6. Line 79: forgo forgot

There is no spelling error in line 79. Because of Gly→X mutations on the triple helix structure, it is challenging to remove an affinity tag and isolate collagen-like domains containing such mutations using trypsin enzyme. For that reason, authors intentionally do not cleave the affinity tag to prevent protein degradation.

Reviewer 2

1. This manuscript by Gahlawat et al described a simple laboratory effort to purify a collagen like protein (CLP) having Gly-to-X mutations that was first expressed as a fusion protein. They provided evidence showing protease TEV is better suited for the removal of the His-tagged V-domain than trypsin because of the folding problem related to the mutation.

a. Yet, there is no data and no mention on the folding of the peptides.

We have added circular dichroism (CD) spectra in Supplementary Information (Fig S1) for the different CLPs demonstrating that the constructs properly fold into a triple helix as evidenced by a minimum and a maximum peak around 198-200 nm and 220-225 nm, respectively.

b. Did the digestion act on monomer during purification or on folded trimer?

The trypsin digestion assays were performed on the folded trimers and the digestion profile was visualized using SDS-PAGE. Due to the inclusion of denaturing chemicals and reducing agents, only the monomers will be seen.

c. Can the triple helix form without the removal of V-domain? If not, how can they claim the varied sensitivity of the fusion protein to proteases is related to the ‘partially folded structure’?

Yes, the bacterial collagen triple helix can form without the removal of V-domain.

2. Figure 1 is missing.

Fig 1 is attached.

3. The optimization experiments are notoriously difficult to reproduce. The authors did not mention the reproducibility of the results

We agree with the reviewer that optimization experiments are challenging. Using the reagents and chemicals listed in the Materials and Methods section of the manuscript, we obtained similar yields and purity of proteins in multiple batches, thus offering reproducible results. Since multiple factors can impact protein expression and purification, which ultimately affects protein yield and purity, it is always recommended to tailor the expression and purification of each protein construct by screening different culturing conditions. We emphasize that optimization is not the main theme of

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Yong Wang

3 May 2023

Purification of recombinant bacterial collagens containing structural perturbations

PONE-D-23-06762R1

Dear Dr. Shreiber,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yong Wang

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All comments have been addressed satisfactorily. I have no additional questions. The use of TEV proteases for purification of CLP has been demonstrated satisfactorily.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

<quillbot-extension-portal></quillbot-extension-portal>

Acceptance letter

Yong Wang

9 May 2023

PONE-D-23-06762R1

Purification of recombinant bacterial collagens containing structural perturbations

Dear Dr. Shreiber:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yong Wang

Academic Editor

PLOS ONE


Articles from PLOS ONE are provided here courtesy of PLOS

RESOURCES